Brett Ley, MD

Pulmonologist

Clinics

ILD Program
400 Parnassus Ave., Fifth Floor
San Francisco, CA 94143
Phone: (415) 353-2577
Fax: (415) 353-8944

Pulmonary Practice at Parnassus
400 Parnassus Ave., Fifth Floor
San Francisco, CA 94143-0359
Phone: (415) 353-2961
Fax: (415) 353-2568

Hours: Monday to Friday
8 a.m. – 5 p.m.

Board Certification

Internal Medicine, American Board of Internal Medicine

Academic Title

Assistant Professor

More about Brett Ley

Education

University of California San Francisco School of Medicine 2008

Residencies

UCSF Medical Center 2012

Selected Research and Publications

  1. Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017 Sep 15; 196(6):756-761.
  2. Ley B. Clarity on Endpoints for Clinical Trials in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 Sep; 14(9):1383-1384.
  3. Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, Golden JA, Jones KD, Batra K, Torrealba J, Garcia CK, Wolters PJ. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017 Aug; 5(8):639-647.
  4. Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE, Collard HR, Lee JS. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. Chest. 2017 11; 152(5):999-1007.
  5. Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, Ryu JH, Jones KD, Cerri S, Manfredi A, Sebastiani M, Gross AJ, Ley B, Wolters PJ, King TE, Kim DS, Collard HR, Lee JS. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Respir Med. 2017 Jun; 127:51-56.
  6. Ley B. A Glimpse into the Future: Automated Quantitative Computed Tomography as a Biomarker in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017 04 01; 195(7):850-852.
  7. Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, Golden JA, King TE, Wolters PJ, Collard HR, Ley B. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax. 2017 May; 72(5):424-429.
  8. Morisset J, Johannson KA, Vittinghoff E, Aravena C, Elicker BM, Jones KD, Fell CD, Manganas H, Dubé BP, Wolters PJ, Collard HR, Ryerson CJ, Ley B. Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest. 2017 03; 151(3):619-625.
  9. Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR. Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016 Sep 15; 194(6):711-8.
  10. Johannson KA, Elicker BM, Vittinghoff E, Assayag D, de Boer K, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Wolters PJ, Collard HR. A diagnostic model for chronic hypersensitivity pneumonitis. Thorax. 2016 10; 71(10):951-4.
  11. Ley B, Collard HR. House of Cards? Testing Fundamental Assumptions in Idiopathic Pulmonary Fibrosis Epidemiology. Am J Respir Crit Care Med. 2015 Nov 15; 192(10):1147-8.
  12. Johannson KA, Ley B, Collard HR. Models of disease behavior in idiopathic pulmonary fibrosis. BMC Med. 2015 Sep 24; 13:165.
  13. Assayag D, Vittinghoff E, Ryerson CJ, Cocconcelli E, Tonelli R, Hu X, Elicker BM, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Shum AK, Wolters PJ, Ryu JH, Collard HR. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med. 2015 Aug; 109(8):1058-62.
  14. Ley B, Bradford WZ, Weycker D, Vittinghoff E, du Bois RM, Collard HR. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015 May; 45(5):1374-81.
  15. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014 Nov 01; 307(9):L681-91.
  16. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, Richeldi L, King TE, Collard HR. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology. 2014 Nov; 273(2):570-9.
  17. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE, Collard HR. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014 Apr; 145(4):723-728.
  18. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013 Nov 25; 5:483-92.
  19. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE, Ryu J, Collard HR. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013 Jul; 144(1):234-240.
  20. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012 May 15; 156(10):684-91.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.